Nivolumab-refractory patients with advanced non-small-cell lung cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.01.015
Abstract: INTRODUCTION Immune checkpoint inhibitors (ICIs) have revolutionised cancer care especially in lung cancer. New response patterns have been described under ICIs such as pseudo-progression or hyper-progressive disease (HPD). The definition of HPD is yet to… read more here.
Keywords: advanced non; nivolumab refractory; refractory patients; lung cancer ... See more keywords